{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:54:39Z","timestamp":1792702479741,"version":"4.5.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:p>Leukemia is a complex and heterogeneous disease, making it challenging to determine the correct treatment. Over the past few decades, there have been few changes in standard medical care. To mitigate this problem, several potential small molecules that target the disease at the molecular level are being investigated for their clinical significance in leukemia treatment. Among them, the cyclin-dependent kinase (CDK) inhibitor palbociclib emerges as a promising therapeutic candidate targeting CDK4\/6. Although palbociclib was approved by the Food and Drug Administration for the treatment of HER2-negative and HR-positive advanced or metastatic breast cancer, its potential in leukemia is still under research. Furthermore, CDK6 has been discovered to have essential roles in leukemic cells beyond its involvement in cell cycle progression, making it a notable target in leukemia. This review comprehensively analyses existing literature on the effectiveness and safety of using palbociclib alone or in combination with other treatments in preclinical and clinical leukemia investigations.<\/jats:p>","DOI":"10.1097\/md.0000000000046873","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:00:50Z","timestamp":1767711650000},"page":"e46873","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Targeting cell cycle in leukemia: \u201cIs palbociclib the game-changer?\u201d: A review"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3848-9297","authenticated-orcid":false,"given":"Muhamad Amir","family":"Azizan","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainul","family":"Abeden","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Haida Natasha","family":"Shamsuddin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-4593","authenticated-orcid":false,"given":"Fadly","family":"Ahid","sequence":"additional","affiliation":[{"name":"Centre for Medical Laboratory Technology Studies, Faculty of Health Sciences, Universiti Teknologi MARA, Puncak Alam, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narazah","family":"Mohd Yusoff","sequence":"additional","affiliation":[{"name":"Clinical Diagnostic Laboratory, Pusat Perubatan USM Bertam, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Nazri","family":"Ismail","sequence":"additional","affiliation":[{"name":"Analytical Biochemistry Research Centre, Universiti Sains Malaysia, Bayan Lepas, Penang, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Kit","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-0912","authenticated-orcid":false,"given":"Asmida","family":"Isa","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Pulau Pinang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","first-page":"904292","article-title":"Disease burden, risk factors, and trends of leukaemia: a global analysis.","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"R4-20260218","first-page":"80","article-title":"The molecular basis of leukemia.","volume":"2004","author":"Gilliland","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R5-20260218","first-page":"249","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"R6-20260218","first-page":"1578","article-title":"How selective are clinical CDK4\/6 inhibitors?","volume":"41","author":"Hendrychov\u00e1","year":"2021","journal-title":"Med Res Rev"},{"key":"R7-20260218","first-page":"289","article-title":"PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients.","volume":"3","author":"Iwata","year":"2017","journal-title":"J Glob Oncol"},{"key":"R8-20260218","first-page":"1926","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer.","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-20260218","first-page":"1925","article-title":"Palbociclib and letrozole in advanced breast cancer.","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20260218","first-page":"493","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"R11-20260218","first-page":"113527","article-title":"Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R12-20260218","first-page":"600227","article-title":"CDK6 is a potential prognostic biomarker in acute myeloid leukemia.","volume":"11","author":"Liu","year":"2021","journal-title":"Front Genet"},{"key":"R13-20260218","first-page":"90","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"R14-20260218","first-page":"13","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"R15-20260218","first-page":"2528","article-title":"CDK6 inhibition: a novel approach in AML management.","volume":"21","author":"Uras","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R16-20260218","first-page":"1355","article-title":"Targeting the CDK6 dependence of Ph+ acute lymphoblastic leukemia.","volume":"12","author":"Porazzi","year":"2021","journal-title":"Genes (Basel)"},{"key":"R17-20260218","first-page":"2624","article-title":"Inducible deletion of CDK4 and CDK6 \u2013 deciphering CDK4\/6 inhibitor effects in the hematopoietic system.","volume":"106","author":"Maurer","year":"2021","journal-title":"Haematologica"},{"key":"R18-20260218","first-page":"182","article-title":"CCND2 is a RUNX1\/ETO target required for leukaemic propagation.","volume":"229","author":"Mart\u00ednez-Soria","year":"2017","journal-title":"Klin P\u00e4diatr"},{"key":"R19-20260218","first-page":"626","article-title":"The oncogenic transcription factor RUNX1\/ETO corrupts cell cycle regulation to drive leukemic transformation.","volume":"34","author":"Martinez-Soria","year":"2018","journal-title":"Cancer Cell"},{"key":"R20-20260218","first-page":"693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer.","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"key":"R21-20260218","first-page":"143","article-title":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.","volume":"37","author":"Ling","year":"2023","journal-title":"Leukemia"},{"key":"R22-20260218","first-page":"1838","article-title":"CDK4\/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity.","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res"},{"key":"R23-20260218","first-page":"101099","article-title":"Efficacy of a combination therapy targeting CDK4\/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia.","volume":"27","author":"Matsuo","year":"2021","journal-title":"Biochem Biophys Rep"},{"key":"R24-20260218","first-page":"243","article-title":"Inhibition of CDK4\/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.","volume":"113","author":"Nakatani","year":"2021","journal-title":"Int J Hematol"},{"key":"R25-20260218","first-page":"51163","article-title":"An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.","volume":"7","author":"Lopez","year":"2016","journal-title":"Oncotarget"},{"key":"R26-20260218","first-page":"2890","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"key":"R27-20260218","first-page":"2878","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance.","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"R28-20260218","first-page":"3987","article-title":"therapeutic vulnerabilities in FLT3-Mutant AML unmasked by palbociclib.","volume":"19","author":"Uras","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R29-20260218","first-page":"1746","article-title":"Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia.","volume":"107","author":"Bride","year":"2022","journal-title":"Haematologica"},{"key":"R30-20260218","first-page":"1","article-title":"CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.","volume":"11","author":"Ketzer","year":"2022","journal-title":"Oncogenesis"},{"key":"R31-20260218","first-page":"94","article-title":"Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia.","volume":"15","author":"Nemoto","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"R32-20260218","first-page":"834","article-title":"MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.","volume":"13","author":"Van Der Linden","year":"2014","journal-title":"Cell Cycle"},{"key":"R33-20260218","first-page":"2879","article-title":"Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.","volume":"2","author":"Matsuo","year":"2018","journal-title":"Blood Adv"},{"key":"R34-20260218","first-page":"2075","article-title":"Pharmacologic inhibition of CDK4\/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"R35-20260218","first-page":"855","article-title":"Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.","volume":"32","author":"Fujita","year":"2018","journal-title":"Leukemia"},{"key":"R36-20260218","first-page":"547","article-title":"Autophagy, a key mechanism of oncogenesis and resistance in leukemia.","volume":"129","author":"Auberger","year":"2017","journal-title":"Blood"},{"key":"R37-20260218","first-page":"299","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence.","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"R38-20260218","first-page":"13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.","volume":"4","author":"Takahashi","year":"2011","journal-title":"J Hematol Oncol"},{"key":"R39-20260218","first-page":"1784","article-title":"Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase.","volume":"17","author":"Delgado","year":"2018","journal-title":"Cell Cycle"},{"key":"R40-20260218","first-page":"161","article-title":"Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia.","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int"},{"key":"R41-20260218","first-page":"2566","article-title":"Forced expression of cyclin-dependent kinase 6 confers resistance of Pro-B acute lymphocytic leukemia to gleevec treatment.","volume":"31","author":"Kuo","year":"2011","journal-title":"Mol Cell Biol"},{"key":"R42-20260218","first-page":"111","article-title":"CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.","volume":"50","author":"Schneeweiss-Gleixner","year":"2019","journal-title":"EBioMedicine"},{"key":"R43-20260218","article-title":"Tight association of autophagy and cell cycle in leukemia cells.","volume":"27","author":"Gschwind","year":"2022","journal-title":"Cell Mol Biol Lett"},{"key":"R43-20260218","first-page":"32"},{"key":"R44-20260218","first-page":"231","article-title":"GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia.","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis"},{"key":"R45-20260218","first-page":"96","article-title":"Glyoxalase 1 inhibitor BBGC suppresses the progression of chronic lymphocytic leukemia and promotes the efficacy of Palbociclib.","volume":"650","author":"Tang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"R48-20260218","first-page":"13","article-title":"A phase I\/II trial of CPX-351 + palbociclib in patients with acute myeloid leukemia.","volume":"136","author":"Nazha","year":"2020","journal-title":"Blood"},{"key":"R49-20260218","first-page":"107075","article-title":"A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.","volume":"129","author":"Wilde","year":"2023","journal-title":"Leuk Res"},{"key":"R50-20260218","first-page":"e30609","article-title":"Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a children\u2019s oncology group study (AINV18P1).","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"R51-20260218","first-page":"4057","article-title":"Phase I study of palbociclib alone and in combination in patients with relapsed and refractory (R\/R) leukemias.","volume":"132","author":"Kadia","year":"2018","journal-title":"Blood"},{"key":"R52-20260218","first-page":"2337","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia.","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"R53-20260218","first-page":"537","article-title":"The aurora kinases in cell cycle and leukemia.","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"R54-20260218","first-page":"1851","article-title":"A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.","volume":"6","author":"Ikezoe","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"R55-20260218","first-page":"1104","article-title":"AML1-ETO and C-KIT mutation\/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R56-20260218","first-page":"7","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"R57-20260218","first-page":"1180","article-title":"Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015\u20132020.","volume":"63","author":"Huntington","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R58-20260218","first-page":"2026","article-title":"Pathways and mechanisms of venetoclax resistance.","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R59-20260218","first-page":"2665","article-title":"The role of autophagy in targeted therapy for acute myeloid leukemia.","volume":"17","author":"Du","year":"2021","journal-title":"Autophagy"},{"key":"R60-20260218","first-page":"1614","article-title":"Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.","volume":"128","author":"Sumitomo","year":"2016","journal-title":"Blood"},{"key":"R61-20260218","first-page":"238","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation.","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"R62-20260218","first-page":"8","article-title":"Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog\/GLI signaling.","volume":"15","author":"Aberger","year":"2017","journal-title":"Cell Commun Signal"},{"key":"R63-20260218","first-page":"e877","article-title":"Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial.","volume":"7","author":"Gaidzik","year":"2023","journal-title":"Hemasphere"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:33:28Z","timestamp":1786041208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046873","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2024-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}